<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for rectal cancer: Neoadjuvant &lt;font style="white-space: nowrap;"&gt;FOLFIRINOX&lt;sup&gt;[1]&lt;/sup&gt;&lt;/font&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for rectal cancer: Neoadjuvant <font style="white-space: nowrap;">FOLFIRINOX<sup>[1]</sup></font></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for rectal cancer: Neoadjuvant <font style="white-space: nowrap;">FOLFIRINOX<sup>[1]</sup></font></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 14 days.<br/> <strong>Duration of therapy:</strong> 6 cycles (3 months).* </td> </tr> <tr> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td><span style="white-space: nowrap;">Oxaliplatin<sup>¶</sup></span></td> <td>85 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL <span style="white-space: nowrap;">D5W<sup>Δ</sup></span> and administer over 2 hours (with leucovorin).</td> <td>Day 1</td> </tr> <tr> <td><span style="white-space: nowrap;">Leucovorin<sup>◊</sup></span></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL <span style="white-space: nowrap;">D5W<sup>Δ</sup></span> and administer over 2 hours (with oxaliplatin).</td> <td>Day 1</td> </tr> <tr> <td><span style="white-space: nowrap;">Irinotecan<sup>§</sup></span></td> <td>180 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL <span style="white-space: nowrap;">D5W<sup>Δ</sup></span> and administer over 90 minutes, after oxaliplatin and leucovorin.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Fluorouracil (FU)</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL 0.9% NS or <span style="white-space: nowrap;">D5W<sup>Δ</sup></span> and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL <span style="white-space: nowrap;">NS.<sup>Δ</sup></span></td> <td>Day 1</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>HIGH (&gt;90% frequency of <span style="white-space: nowrap;">emesis).<sup>¥</sup></span></li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>No standard premedication regimen.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Oxaliplatin and FU are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with G-CSF was not mandated in the trial unless patients developed febrile neutropenia, grade 4 neutropenia lasting more than 1 week, or an infection occurring during grade 3 or 4 neutropenia; it was also advised if a cycle was delayed for a week or longer because of neutropenia. However, given the high risk of grade 3 or 4 neutropenia with this regimen, primary prophylaxis with G-CSF is used at many institutions.</li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>A lower starting dose of oxaliplatin and irinotecan may be needed for severe renal <span style="white-space: nowrap;">insufficiency.<sup>[2,3]</sup></span> A lower starting dose of irinotecan and FU may be needed for patients with hepatic <span style="white-space: nowrap;">impairment.<sup>[3,4]</sup></span></li> <li><strong>NOTE:</strong> We do not recommend administration of FOLFIRINOX unless serum bilirubin is normal, or if isolated bilirubin elevation is attributed to Gilbert syndrome.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease and chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan="3"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each <span style="white-space: nowrap;">infusion.<sup>[2]</sup></span> Prolongation of the oxaliplatin infusion time from 2 to 6 hours may mitigate acute neurotoxicity.</li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Cardiac issues</strong></td> <td colspan="3"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Electrolytes (especially potassium and magnesium), and liver and renal function prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Irinotecan is associated with early and late diarrhea, both of which may be <span style="white-space: nowrap;">severe.<sup>[3]</sup></span> For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored, and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should be provided as needed.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Assess changes in neurologic function prior to each treatment.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Do not retreat unless neutrophil count is ≥1500/microL and platelets are ≥100,000/microL.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neutropenia</strong></td> <td colspan="3"> <ul> <li>The following dose reduction guidelines for hematologic toxicity were provided in the original <span style="white-space: nowrap;">protocol:<sup>[1]</sup></span> If day 1 treatment delayed for granulocytes &lt;1500/microL, or febrile neutropenia or grade 4 neutropenia &gt;7 days: Reduce irinotecan dose to 150 mg/m<sup>2</sup> and add G-CSF. For second occurrence: Reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and reduce FU infusion by 20% (1000 mg/m<sup>2</sup> per day). If nonrecovery after 2-week delay or third occurrence of granulocytes &lt;1500/microL on day 1, or febrile neutropenia or grade 4 neutropenia at any time during cycle, discontinue treatment.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Thrombocytopenia</strong></td> <td colspan="3"> <ul> <li>The following dose reduction guidelines for hematologic toxicity were provided in the original <span style="white-space: nowrap;">protocol:<sup>[1]</sup></span> If day 1 treatment delayed for platelet count &lt;100,000/microL, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and reduce continuous infusion FU by 25% (900 mg/m<sup>2</sup> per day). For second occurrence, reduce irinotecan dose to 150 mg/m<sup>2</sup>. If nonrecovery after 2-week delay or third occurrence of platelets &lt;100,000/microL, discontinue treatment. For grade 3 or 4 thrombocytopenia <strong>during</strong> treatment, reduce oxaliplatin dose to 60 mg/m<sup>2</sup>. For the second occurrence, reduce dose of irinotecan to 150 mg/m<sup>2</sup> and the dose of infusional FU by 25% (900 mg/m<sup>2</sup> per day). Discontinue irinotecan for third occurrence.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Diarrhea</strong></td> <td colspan="3"> <ul> <li>Loperamide should be initiated from the first liquid or soft stool (2 capsules orally, then 1 every 2 hours for at least 12 hours after the last liquid stool, without exceeding a total treatment duration of 48 hours); for diarrhea persisting more than 48 hours, begin a fluoroquinolone <span style="white-space: nowrap;">antibiotic.<sup>[1]</sup></span> Hospitalize for parenteral hydration and antidiarrhea treatment for persistent and/or severe diarrhea.</li> <li>Do not retreat with FOLFIRINOX until resolution of diarrhea for at least 24 hours without antidiarrheal medication. For diarrhea grade 3 or 4, or diarrhea with fever and/or grade 3 or 4 neutropenia, reduce irinotecan dose to 150 mg/m<sup>2</sup>. For second occurrence, reduce the oxaliplatin dose to 60 mg/m<sup>2</sup> and the continuous infusion FU dose by 25% (900 mg/m<sup>2</sup> per day). Discontinue irinotecan for third occurrence.</li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for DPD deficiency.</li> <li>Refer to UpToDate topics on chemotherapy-associated diarrhea, constipation and intestinal perforation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Mucositis or hand-foot syndrome</strong></td> <td colspan="3"> <ul> <li>For grade 3 to 4 toxicity, reduce infusional FU by 25% (900 mg/m<sup>2</sup> per day).</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Pulmonary toxicity</strong></td> <td colspan="3"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is <span style="white-space: nowrap;">excluded.<sup>[2]</sup></span></li> <li>Refer to UpToDate topics on pulmonary toxicity associated with antineoplastic therapy, cytotoxic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurologic toxicity</strong></td> <td colspan="3"> <ul> <li>For grade 3 paresthesias/dysesthesias lasting &lt;14 days or grade 2 symptoms persisting between cycles, decrease oxaliplatin dose to <span style="white-space: nowrap;">65 mg/m<sup>2</sup>.<sup>[1]</sup></span> Discontinue oxaliplatin for any grade 4, or grade 3 paresthesia/dysesthesia that persists between cycles.</li> <li>There is no recommended dose for resumption of FU administration following development of hyperammonemic encephalopathy, acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances; the drug should be permanently <span style="white-space: nowrap;">discontinued.<sup>[4]</sup></span></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiotoxicity</strong></td> <td colspan="3"> <ul> <li>Cardiotoxicity observed with FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, ECG changes, and cardiomyopathy. There is no recommended dose for resumption of FU administration following development of cardiac toxicity, and the drug should be <span style="white-space: nowrap;">discontinued.<sup>[1,4]</sup></span></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="3"> <ul> <li>Any other toxicity ≥grade 2, except anemia and alopecia, can justify dose reduction if medically <span style="white-space: nowrap;">indicated.<sup>[1]</sup></span></li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; D5W: 5% dextrose in water; NS: normal saline; G-CSF: granulocyte-colony stimulating factors; QT: time between the start of the Q wave and the end of the T wave (heart electrical cycle); ECG: electrocardiogram; CBC: complete blood count; DPD: dihydropyrimidine dehydrogenase; NCCN: National Comprehensive Cancer Network.<br/>
* Chemoradiotherapy was planned to begin 1 to 3 weeks after the last FOLFIRINOX cycle.<br/>
¶ Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.<br/>
Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
◊ Leucovorin dose is given for d,l-racemic <font style="white-space: nowrap;">mixture.<sup>[5]</sup></font> Use half the dose for LEVOleucovorin (l-leucovorin).<br/>
§ A lower initial dose of irinotecan may be considered for patients with poor performance status or increased bilirubin <font style="white-space: nowrap;">levels.<sup>[3]</sup></font> Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert syndrome) and whether testing for this allele should be carried out prior to starting irinotecan are controversial. Refer to UpToDate topic on "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation".<br/>
¥ At many institutions, regimens that combine oxaliplatin with irinotecan on day 1 are considered highly emetogenic, warranting the use of a neurokinin-1 receptor antagonist on day 1. The NCCN considers this and similar regimens as moderately emetogenic.</div><div class="graphic_reference">References:
<ol>
<li>Conroy T, et al. Lancet Oncol 2021; 22:702.</li>
<li>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
<li>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
<li>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
<li>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
</ol></div><div id="graphicVersion">Graphic 134372 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
